DRUG PRODUCT REGISTRATION IN SEMI-REGULATED MARKET
Journal Title: International Journal of Drug Regulatory Affairs - Year 2013, Vol 1, Issue 2
Abstract
There found a diversity of regulatory requirement in Semi regulated market. This region consists of mainly the countries from Asia pacific, Latin America, Eastern Europe, Africa and Gulf countries. Countries from Asia pacific and Gulf have somewhat harmonized their regulatory environment through The Association of Southeast Asian Nations (ASEAN) and Gulf Co-operation Council (GCC) organizations, ROW countries yet to be harmonized regulations in their respective regions. The urgent requirement to rationalize & harmonize regulation was required by instance of rising cost of health care, research & development and to meet the public requirement for safe and efficacious treatments to patient in need. ICH committee has given priority to harmonize the format of reporting data for quality, safety and Efficacy in the application dossier. The commercial significance of ROW markets is increasing globally. It is crucial that pharmaceutical companies keep up-to-date with the latest regulatory developments to ensure their place on the ROW market. This paper favors the regulatory processes for gaining marketing authorization in ROW countries in terms of technical data requirement for the dossier.
Authors and Affiliations
Badjatya Jitendra Kumar, Bodla Ramesh
Keywords
Related Articles
- EP ID EP336473
- DOI -
- Views 108
- Downloads 0
Simultaneous estimation of xanthine alkaloids (Theophylline, Theobromine and Caffeine) by High-Performance Liquid Chromatography
Methylxanthines are mainly a group of phytochemicals which are derived from purine base xanthine. These xanthines are obtained from plant as a result of secondary metabolism. There are various physiological actions that...
Preliminary requirement for ANDA Filing
USFDA is very critical regulated agency for submission. This review reveals how to submit an Abbreviated New Drug Application (ANDA) as per FDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)...
Regulatory overview of biosimilars in Europe
A biosimilar is a biological medicine similar, but not identical, to an already registered reference bio therapeutic product in terms of quality, safety, and efficacy. These drugs are also called as biosimilar products„,...
Regulation of Blood and Blood products in India, USA and EU
Blood and blood products are precious commodity which gives life to another person. Though we have immense discoveries and invention in science and technology, yet we cannot make blood hence, human blood has no substitut...
FORMULATION, DEVELOPMENT AND OPTIMIZATION OF MODIFIED RELEASING PELLETS OF DRUG CARVEDILOL
The main objectives of present work was to design and evaluate modified releasing pellets of drug, Carvedilol, in respect to increase patient compliance and therapeutically benefits. The modified releasing pellets were m...